Spruce Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 29
- Market Cap
- $19.7M
- Website
- http://www.sprucebio.com
Spruce Biosciences Acquires Tralesinidase Alfa for Sanfilippo Syndrome Type B Treatment with BLA Submission Planned for 2026
Spruce Biosciences has acquired tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B, a neurodegenerative and fatal genetic disease with no FDA-approved treatments.
FDA Grants Priority Review to Crinecerfont for Congenital Adrenal Hyperplasia
The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH).